MIRA Pharmaceuticals, Inc. Common Stock (MIRA)

Official site

HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

$0.66

-0.02 (-3.52%)

Market Cap: $28.00M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

50%(5/10)

Avg Surprise

-34.75%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.03

Range$-0.03 - $-0.03

1 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate DriftChange to current

90d ago$0.00n/a

60d ago$0.00n/a

30d ago$0.00n/a

7d ago$0.00n/a

Current$-0.03

Revenue Consensus

Range$0 - $0

1 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Sep 30, 2026Sep 26EST	-	$-0.03	$-0.03 - $-0.03	-	-	1	No revisions (30d)	-
Jun 30, 2026Jun 26 Reported Aug 12, 2026Reported Aug 12	$-0.03	N/A	-	N/A	Beat	-	-	+66.7%
Mar 31, 2026Mar 26 Reported May 14, 2026Reported May 14	$-0.03	N/A	-	N/A	Beat	-	-	+75.1%
Dec 31, 2025Dec 25 Reported Mar 31, 2026Reported Mar 31	$-0.14	$-0.08	$-0.08 - $-0.08	-78.38%	Miss	1	1 0 30d	+18.5%
Sep 30, 2025Sep 25 Reported Nov 13, 2025Reported Nov 13	$-0.07	$-0.08	$-0.08 - $-0.08	+12.50%	Beat	1	0 1 30d	+50.0%
Jun 30, 2025Jun 25 Reported Aug 14, 2025Reported Aug 14	$-0.09	$-0.13	$-0.15 - $-0.11	+30.77%	Beat	2	No revisions (30d)	+18.2%
Mar 31, 2025Mar 25 Reported May 14, 2025Reported May 14	$-0.11	$-0.14	$-0.15 - $-0.14	+21.43%	Beat	2	No revisions (30d)	+8.3%
Dec 31, 2024Dec 24 Reported Mar 28, 2025Reported Mar 28	$-0.17	$-0.13	$-0.18 - $-0.08	-34.62%	Miss	2	0 1 30d	+52.7%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-0.14	$-0.15	$-0.18 - $-0.13	+6.67%	Beat	2	No revisions (30d)	+46.2%
Jun 30, 2024Jun 24 Reported Aug 13, 2024Reported Aug 13	$-0.11	$-0.11	$-0.12 - $-0.08	+0.00%	Beat	3	No revisions (30d)	-10.0%
Mar 31, 2024Mar 24 Reported Apr 1, 2024Reported Apr 1	$-0.12	$-0.10	$-0.10 - $-0.10	-20.00%	Miss	1	0 1 30d	-
Dec 31, 2023Dec 23 Reported Feb 28, 2024Reported Feb 28	$-0.37	$-0.23	$-0.23 - $-0.23	-60.87%	Miss	0	No revisions (30d)	-
Sep 30, 2023Sep 23 Reported Nov 13, 2023Reported Nov 13	$-0.26	$-0.08	-	-225.00%	Miss	-	-	-
Jun 30, 2023Jun 23 Reported Sep 15, 2023Reported Sep 15	$-0.10	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-2.44	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-217.10%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	63.24x
Current Ratio	200.08x	Quick Ratio	200.08x
Trading Statistics
Beta	1.49	Avg Volume	160.57K
52-Week High	$2.45	52-Week Low	$0.60

Technical Indicators Dashboard

Moving Averages

SMA 10$0.70

SMA 20$0.78

SMA 50$0.77

SMA 200$1.01

EMA 10$0.71

EMA 20$0.74

EMA 50$0.78

EMA 200$0.97

MACD

Line: -0.03Signal: -0.02Hist: -0.01

ADX

ADX: 23.9+DI: 17.7-DI: 30.2

Aroon & PSAR

Aroon Up36.0

Aroon Down60.0

PSAR$0.74

Bollinger Bands

Upper Band$0.96

Lower Band$0.60

%B Position4516%(Upper)

Band Width0.15

RSI (14-Day)

Neutral

37.5

Momentum Oscillators

Stoch %K16.8

Stoch %D21.8

Williams %R-86.9

ROC (10d)-9.0%

Momentum-0.06

CCI (20d)-106.7

MFI (14d)19.6

Volatility Measures

ATR (14d)$0.06(9.1%)

StdDev (20d)0.09

Hist Vol86.8%(High)

Volume Flow

VWAP$0.65

OBV240.8M

AD Line-108.7M

CMF (20d)0.271

Volume Metrics

Avg Vol (20d)165.9K

Vol Ratio0.8x

VWMA (20d)$0.79

Pivot Points

R3$0.72

R2$0.70

R1$0.69

Pivot Point$0.68

S1$0.67

S2$0.65

S3$0.64

Advanced Oscillators

TSI-15.13

Ultimate Osc47.9

KST-71.91

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Cost of Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0	$0	$0	N/A	$0
Gross Profit	$0	$0	N/A	$0	$0	$0	N/A	$0	$0	$0	N/A	$0

Operating Expenses	$1.16M	$1.10M	$5.82M	$1.32M	$1.55M	$1.81M	$2.44M	$2.08M	$1.73M	$1.77M	$3.06M	$3.16M
R&D	$705,789	$524,781	$496,543	$412,639	$496,197	$314,404	$861,441	$1.07M	$614,462	$762,276	$387,123	$1.02M
SG&A	$450,330	$578,698	$5.33M	$904,346	$1.05M	$1.49M	$1.58M	$1.01M	$1.12M	$1.01M	$2.67M	$2.14M
Operating Income	$-1,156,119	$-1,103,479	$-5,824,827	$-1,316,985	$-1,546,100	$-1,805,200	$-2,437,800	$-2,081,619	$-1,730,722	$-1,768,187	$-3,056,354	$-3,160,084

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$39,397	$0	$0	$0
Interest Expense	$-35,130	$-44,909	$158,494	$-15,697	$-8,623	$-21,421	$0	$-37,752	$0	$-50,416	$2.73M	$427,732
Income Before Tax	$-1,208,534	$-1,150,152	$-5,983,321	$-1,137,673	$-1,537,712	$-1,783,779	$-2,399,696	$-2,043,867	$-1,691,325	$-1,717,771	$-5,787,376	$-3,587,816
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-1,208,534	$-1,150,152	$-5,983,321	$-1,137,673	$-1,537,712	$-1,783,779	$-2,399,696	$-2,043,867	$-1,691,325	$-1,717,771	$-5,787,376	$-3,587,816

EBITDA	$-1,243,664	$-1,195,061	$-5,824,827	$-1,153,370	$-1,546,335	$-1,805,200	$-2,437,800	$-2,081,619	$-1,730,722	$-1,768,187	$-3,056,354	$-2,720,709
EBIT	$-1,243,664	$-1,195,061	$-5,824,827	$-1,153,370	$-1,546,335	$-1,805,200	$-2,437,800	$-2,081,619	$-1,730,722	$-1,768,187	$-3,056,354	$-3,160,084

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about MIRA

News

Total assets of MIRA Pharmaceuticals, Inc. – HAN:K6S

This article provides financial information for MIRA Pharmaceuticals, Inc. (K6S) listed on the Hannover Stock Exchange. It specifically focuses on the company's total assets...

TradingView•Sep 29, 2026 9:53 AM ET9/29/26•Neutral

What's Behind MIRA Pharmaceuticals, Inc.'s (MIRA) Big Moment in Cannabis Stocks?

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is gaining attention in the cannabis stocks sector due to the completion of dose-range toxicology work for MIRA-Fifty-Five...

Kalkine Media•Sep 25, 2026 8:53 AM ET9/25/26•Somewhat-Bullish

MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review By Investing.com

MIRA Pharmaceuticals has submitted the Phase 2a protocol for Ketamir-2 to an Institutional Review Board for review...

Investing.com Canada•Sep 17, 2026 8:25 PM ET9/17/26•Bullish

Maxim Group Initiates MIRA Pharmaceuticals(MIRA.US) With Buy Rating, Announces Target Price $3.5

Maxim Group has initiated coverage on MIRA Pharmaceuticals (MIRA.US) with a Buy rating. The firm has set a price target of $3.5 for the company's stock. This initiation suggests a positive outlook from Maxim Group...

Moomoo•Sep 17, 2026 8:24 PM ET9/17/26•Bullish

MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review

MIRA Pharmaceuticals has submitted the Phase 2a protocol for its drug Ketamir-2 to an Institutional Review Board for evaluating its effectiveness in treating chemotherapy-induced peripheral neuropathy (CIPN). The company...

Investing.com•Sep 17, 2026 11:18 AM ET9/17/26•Bullish

MIRA Valuation and Fair Value

P/E: -2.4x
P/B: 3.4x

See GNG's fair value

MIRA Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -217.1%

MIRA Competitors

Company	Ticker
Evoke Pharma Inc	EVOK
Transcode Therapeutics Inc	RNAZ
Sangamo Therapeutics Inc	SGMO
OneMedNet Corp.	ONMD
Picard Medical, Inc.	PMI
Plus Therapeutics Inc	PSTV
Nortech Systems Incorporated	NSYS
India Globalization Capital Inc	IGC

Sector: Healthcare

MIRA Earnings: Beat Rate and Next Report

Beat rate: 4 of 8 quarters (50.0%)
Average surprise: -7.7%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.03
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 0 down

Frequently Asked Questions About MIRA

Does MIRA pay dividends?

MIRA Pharmaceuticals, Inc. Common Stock (MIRA) does not currently pay a regular dividend.

What is MIRA's market cap?

MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has a market capitalization of $28.00M with a current stock price of $0.66.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In